Trial Profile
Genetic-Disease Outcome Consortium-Aliskiren Study
Status:
Discontinued
Phase of Trial:
Phase IV
Latest Information Update: 25 Nov 2019
Price :
$35
*
At a glance
- Drugs Aliskiren (Primary) ; Amlodipine
- Indications Diabetic nephropathies; Hypertension
- Focus Therapeutic Use
- Acronyms G-DOC-ALIS
- 22 Nov 2019 Planned End Date changed from 1 Jun 2013 to 1 Dec 2012.
- 22 Nov 2019 Status changed from recruiting to discontinued.
- 18 May 2011 New trial record